文献速递肝胆胰外科围术期管理与 ERAS

胰切除术后常规使用帕瑞肽的结局

Outcomes after Pancreatectomy with Routine Pasireotide Use.
PubMed 文献 · J Am Coll Surg · 2018-11-07

与既往随机试验安慰剂组(n=148)相比,帕瑞肽组主要终点发生率为13.3% vs 20.9%(OR 0.58;95%CI 0.37-0.92;P=0.020),胆漏更低(0.6% vs 3.4%;P=0.014),其他并发症无变化。

要点

  • 常规使用帕瑞肽后临床相关胰瘘或脓肿发生率为13.3%,接近随机试验效果。
  • 与历史安慰剂组相比,帕瑞肽组主要终点风险显著降低(OR 0.58;95%CI 0.37-0.92)。
  • 帕瑞肽组胆漏发生率更低(0.6% vs 3.4%;P=0.014),其他并发症无变化。

核心结论

  • 常规使用帕瑞肽后胰切除术后临床相关胰瘘或脓肿发生率为13.3%,与随机试验中观察到的效果近似。

研究设计与样本

  • 帕瑞肽术前给药,术后每日两次持续7天或至出院;主要终点为需干预的临床相关胰瘘或脓肿。
  • 采用逻辑回归与既往随机试验安慰剂组(n=148)比较,并控制已知胰瘘危险因素。

主要发现

  • 帕瑞肽组主要终点发生率为13.3%,安慰剂组为20.9%(OR 0.58;95%CI 0.37-0.92;P=0.020)。
  • 帕瑞肽组胆漏发生率为0.6%,安慰剂组为3.4%(P=0.014)。
  • 帕瑞肽组ASA评分较高者占69%,安慰剂组为54%(P<0.001);高危病例(小胰管和软腺体)占47%,安慰剂组为36%(P=0.030)。
  • 其他并发症无变化,未识别出更可能获益的亚群。

关键数值与推荐

  • 主要终点:需干预的临床相关胰瘘或脓肿,帕瑞肽组13.3% vs 安慰剂组20.9%(OR 0.58;95%CI 0.37-0.92;P=0.020)。
  • 胆漏:帕瑞肽组0.6% vs 安慰剂组3.4%(P=0.014)。

临床怎么用

  • 胰切除术后可考虑常规围术期使用帕瑞肽以降低临床相关胰瘘或脓肿风险。
  • 使用帕瑞肽未增加其他并发症,但需注意本研究为单中心观察性比较。

局限性

  • 本研究为单中心观察性研究,与历史随机试验安慰剂组比较,非同期随机对照。
  • 帕瑞肽组ASA评分和高危病例比例均高于安慰剂组,可能存在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Morbidity after pancreatectomy is commonly due to leakage of exocrine secretions resulting in abscess or pancreatic fistula (PF). Previously, we authored a double-blind randomized controlled trial demonstrating that perioperative pasireotide administration lowers abscess or PF formation by >50%. Accordingly, we adopted pasireotide use as standard practice after pancreatectomy in October 2014 and hypothesized a similar PF/abscess rate reduction would be observed. STUDY DESIGN: A prospectively maintained database was queried for all patients who underwent pancreatectomy between October 2014 and July 2017. Pasireotide was administered preoperatively and twice daily for 7 days postoperatively or until discharge. The primary end point was clinically relevant PF/abscess requiring procedural intervention, identical to the earlier trial outcomes. Logistic regression was used to compare outcomes with the placebo arm of the earlier randomized trial and to control known PF risk factors. RESULTS: During the 34-month study period, 652 patients underwent pancreatectomy (211 distal pancreatectomy, 441 pancreaticoduodenectomy). Compared with the historical placebo group (n = 148), the observational group had an increased prevalence of higher American Society of Anesthesiologists scores (69% vs 54%; p < 0.001) and high-risk cases (small duct and soft gland, 47% vs 36%; p = 0.030). The primary end point occurred in 13.3% of patients receiving pasireotide vs 20.9% in the placebo arm of the earlier trial trial (odds ratio 0.58; 95% CI 0.37 to 0.92; p = 0.020). Biliary leakage was lower in those receiving pasireotide (0.6% vs 3.4%; p = 0.014), and other morbidity was unchanged. No subpopulation was identified more likely to benefit from pasireotide. CONCLUSIONS: At our center, adoption of pasireotide has allowed us to achieve a clinically significant abscess or pancreatic leak rate of 13.3%, approximating the effect observed in the randomized trial of pasireotide during routine surgical practice.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Kunstman JW, Goldman DA, Gönen M, et al. Outcomes after Pancreatectomy with Routine Pasireotide Use. J Am Coll Surg. 2018. PMID: 30414453. doi:10.1016/j.jamcollsurg.2018.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。